Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects

por Tsukamoto, Naohiro, Takahashi, Naoki, Itoh, Hiroshi, Pouliquen, Isabelle
Publicado 2015

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing

por Best, Nicky, Price, Robert G., Pouliquen, Isabelle J., Keene, Oliver N.
Publicado 2021

Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab

por Pouliquen, Isabelle J., Kornmann, Oliver, Barton, Sharon V., Price, Jeffrey A., Ortega, Hector G.
Publicado 2015

The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial

por Shabbir, Shaila, Pouliquen, Isabelle J., Bentley, Jane H., Bradford, Eric S., C. Kaisermann, Morrys, Albayaty, Muna
Publicado 2019

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

por Gupta, Atul, Pouliquen, Isabelle, Austin, Daren, Price, Robert G., Kempsford, Rodger, Steinfeld, Jonathan, Bradford, Eric S., Yancey, Steven W.
Publicado 2019

A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma

por Singh, Dave, Fuhr, Rainard, Bird, Nicholas P., Mole, Sarah, Hardes, Kelly, Man, Yau Lun, Cahn, Anthony, Yancey, Steven W., Pouliquen, Isabelle J.
Publicado 2021